Inovio Pharmaceuticals Inc. [INO] stock prices are up 7.19% to $1.79 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The INO shares have gain 7.83% over the last week, with a monthly amount glided 17.76%, and seem to be holding up well over a long-time horizon.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
On 2, February 2023, INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®). In a post published today on Yahoo Finance, INO-4201 found to be well-tolerated in the trial.
From an analyst’s perspective:
Inovio Pharmaceuticals Inc. [NASDAQ: INO] stock has seen the most recent analyst activity on November 09, 2022, when Maxim Group downgraded its rating to a Hold. Previously, BofA Securities downgraded its rating to Underperform on November 01, 2022, and kept the price target unchanged to $2. Oppenheimer downgraded its rating to a Perform. BofA Securities upgraded its rating to a Neutral and raised its price target to $10 on January 21, 2022. In a note dated September 10, 2021, BofA Securities downgraded an Underperform rating on this stock and revised its target price from $9 to $8.
The stock price of Inovio Pharmaceuticals Inc. [INO] has been fluctuating between $1.38 and $4.14 over the past year. Currently, Wall Street analysts expect the stock to reach $2.33 within the next 12 months. Inovio Pharmaceuticals Inc. [NASDAQ: INO] shares were valued at $1.79 at the most recent close of the market. An investor can expect a potential return of 30.17% based on the average INO price forecast.
Analyzing the INO fundamentals
The most recent quarter, Inovio Pharmaceuticals Inc. [NASDAQ:INO] reported sales of 9.15 billion, representing a surge of 187.50%. Gross Margin for this corporation currently stands at -166.56% with Operating Margin at -17535.79%, Pretax Margin comes in at -17085.39%, and Net Margin reading is -17109.87%.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.7033 points at the first support level, and at 1.6167 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.8733, and for the 2nd resistance point, it is at 1.9567.
Inovio Pharmaceuticals Inc. [INO] reported earnings per share of -$0.46 for its fiscal quarter that ended on 6/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.31/share, meaning a difference of -$0.15 and a surprise factor of -48.40%. By comparison, the stated earnings for the previous quarter ended on 3/30/2022 were -$0.36 per share as compared to estimates of -$0.34 per share, a difference of -$0.02 representing a surprise of -5.90%.
Ratios To Look Out For
It’s worth pointing out that Inovio Pharmaceuticals Inc. [NASDAQ:INO]’s Current Ratio is 3.70. In addition, the Quick Ratio stands at 6.82 and the Cash Ratio stands at 6.10. Considering the valuation of this stock, the price to sales ratio is 587.16, the price to book ratio is 2.71.
Transactions by insiders
Recent insider trading involved Weiner David B., Director, that happened on Aug 11 when 11875.0 shares were sold. Director, BENITO SIMON X completed a deal on Jul 20 to sell 2000.0 shares. Meanwhile, Director Weiner David B. sold 9000.0 shares on May 16.